GENPREX Cash Flow from Financial Activities 2017-2025 | GNPX

GENPREX cash flow from financial activities from 2017 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities

GENPREX Cash Flow from Financial Activities 2017-2025 | GNPX

GENPREX cash flow from financial activities from 2017 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B